ERAS Program Implementation for MIPD
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19+
SponsorSeoul National University Hospital
About this trial
To evaluate the impact of an Enhanced Recovery After Surgery (ERAS) program on postoperative recovery in patients undergoing minimally invasive pancreatoduodenectomy (MIPD)
Eligibility criteria
Qualifiers
Age ≥ 19 years, scheduled for standard minimally invasive (robotic or laparoscopic) pancreatoduodenectomy for periampullary tumors
ECOG performance status of 0 or 1 at screening
Able to provide written informed consent, understand study procedures, and complete patient-reported questionnaires
ASA physical status classification I-III
Disqualifiers
Hypersensitivity to fentanyl or ropivacaine
Cognitive impairment preventing independent use of patient-controlled analgesia or completion of questionnaires
Major internal medical or psychiatric disorders affecting treatment response
Severe hepatic or renal dysfunction
Trial design
Treatments tested in this trial
- Conventional
- ERAS
Treatment groups
140 Participants
are divided into 2 treatment groupsLocations
1Seoul National University Hospital03080, Daehak-ro, Jongno-guSeoul, South Korea
Sponsors and collaborators
Seoul National University Hospital
Lead sponsor
SMG-SNU Boramae Medical Center
Collaborator
Korea University Anam Hospital
Collaborator
Source ClinicalTrials.gov